Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver

Medical Hypotheses

Volumn 66, Issue 4, 2006, Pages 844-846

  Yamagishi, S ^a   Nakamura, K ^a   Matsui, T ^a   Sato, T ^b   Takeuchi, M ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTILIPEMIC AGENT; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CHOLESTEROL INTAKE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HYPERCHOLESTEROLEMIA; INSULIN SENSITIVITY; INTESTINE ABSORPTION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK REDUCTION; SENSITIZATION;

ADIPONECTIN; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; FATTY LIVER; HUMANS; INTESTINAL ABSORPTION; INTESTINES;

EID: 31844452256     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.08.022     Document Type: Article

References (11)

1. T. Sudhop, D. Lutjohann, and K. Bergmann Sterol transporters: targets of neutral sterols and new lipid lowering drugs Pharmacol Therapeut 105 2005 333 341
2. R.H. Knopp, C.A. Dujovne, and A.L.E. Beaut Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies Int J Clin Pract 57 2003 363 368
3. L. Simons, M. Tonkon, and L. Masana Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome Curr Med Res Opin 20 2004 1437 1445
4. M.H. Davidson, C.M. Ballantyne, and B. Kerzner Efficacy and safety of ezetimibe coadministered with statins: randomized, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia Int J Clin Pract 58 2004 746 755
5. R.C. Turner, H. Millns, and H.A. Neil Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 317 1998 693 694
6. H. Gylling, and T.A. Miettinen Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease Atherosclerosis 126 1996 325 332
7. S.W. Altmann, H.R. Davis Jr, and L.J. Zhu Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption Science 303 2004 1201 1204
8. J.P. Davies, C. Scott, and K. Oishi Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia J Biol Chem 280 2005 12710 12720
9. E.M. Brunt Nonalcoholic steatohepatitis Semin Liver Dis 24 2004 3 20
10. S. Yamagishi, K. Nakamura, and H. Inoue Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH) Med Hypotheses 65 2005 377 379
11. K. Kobayashi Adipokines: therapeutic targets for metabolic syndrome Curr Drugs Targets 6 2005 525 529